Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

MUSC reveals new bladder cancer diagnostic tool

Medical University Of South Carolina : 11 March, 2008  (Company News)
A new diagnostic tool to detect and monitor bladder cancer has been unveiled by the Medical University of South Carolina (MUSC) Foundation for Research and Development.
Current tests for bladder cancer have shown to be accurate for only 40 percent of diagnoses. MUSC's new test has demonstrated 90 percent accuracy (100 percent specificity) in human urine samples of patients with various degrees of bladder cancer, confirming a newly discovered cell receptor's efficacy in diagnosing that cancer.

The new cell receptor is found on cancerous cells. When the receptor sloughs off the cancer cells, it can be found in urine and prostatic fluid (in men). The first of its kind, the receptor offers great potential as a non- invasive, easy-to-make dipstick or rapid urine test that could transform the screening and diagnosis process for bladder cancer. MUSC’s Omar Moussa, PhD, Dennis Watson, PhD, and Perry Halushka, PhD discovered the receptor.

Patients undergo bladder cancer screening if they are determined to have certain risk factors including a previous diagnosis of bladder cancer, birth defects of the bladder, advanced age (over 55), or work-related exposure to certain chemicals.

Bladder cancer affects males more than women, as well as more whites than other ethnicities, according to the American Cancer Society. The organization estimates that of the approximately 69,000 new bladder cancer cases in the USA this year, almost 52,000 will be in men.

Current studies report that patients with successfully treated bladder cancer still have a 50 to 80 percent recurrence rate, making this potential urine-based test perfect for home cancer recurrence monitoring. For the methods most routinely used to detect or monitor bladder cancer, convenience, comfort and pain are issues related to patients' experiences with those tests.

The new diagnostic test from MUSC could eliminate the need for invasive tests like cystoscopy and biopsies that can be painful or cause medical complications.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo